Tofacitinib (CAS 477600-75-2) – Immunomodulator API

Tofacitinib (CAS 477600-75-2) is a high-purity Janus kinase (JAK) inhibitor and immunomodulator API, featuring a targeted mechanism that blocks JAK1/JAK3 signaling pathways. Its molecular structure selectively inhibits cytokine-mediated immune responses, reducing abnormal inflammation and immune hyperactivity without broad immunosuppression. Produced under GMP-compliant processes, it ensures ultra-high purity, consistent bioactivity, and adherence to international pharmaceutical standards for immunology drugs.

This premium API is a core raw material for pharmaceutical manufacturers developing treatments for autoimmune diseases. It is widely applied in formulating medications for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, effectively alleviating joint pain, swelling, and mucosal inflammation. With proven clinical efficacy in improving patient quality of life, it addresses the critical demand for targeted autoimmune therapies. For R&D teams and production enterprises, it provides a trusted solution to advance precision immunology care.